THE FREQUENCY AND CLINICAL USEFULNESS OF CA 19-9 IN THE WORK UP OF OVARIAN MALIGNANCY

Authors

  • Ahmad Arsalan Tahir Department of Surgery Mid Cheshire NHS Foundation Trust - UK
  • Sahifa Kamal Department of Surgery Peshawar Institute of Medical Sciences, Peshawar - Pakistan
  • Rashid Waheed Department of Surgery Khyber Teaching Hospital, Peshawar - Pakistan

Keywords:

Ovaries, Cancer, Tumer Markers

Abstract

Objectives: To assess the frequency and clinical usefulness of CA 19-9 in the workup of ovarian malignancy.
Material and Methods: This cross sectional study included 30 patients with histologically confirmed ovarian adenocarcinomas,
was conducted in the departments of medicine, surgery and obstetrics & gynecology of Peshawar Institute of
Medical Sciences, Peshawar, Pakistan from January 2016 to October 2017. The patients were initially recruited from and
then followed up in surgical and gynecological OPD. Each patient underwent a measurement of CA 19-9. The frequency
of elevated CA 19-9 was checked and was sub-stratified amongst age group, ethnicity, tumor bulk and smoking status.
Results: Mean age of the participants was 54.30 years ±10.52, mean CA 19-9 was 64.67± 32.65 and the mean tumor
size in cm on CT pelvis was 4.83± 1.76. 36.7% (n=11) had extensive disease with distant metastasis while 50%
(n=15) were either abusing tobacco or were exposed to passive smoking at home. The frequency of elevated CA 19-9
in patients with ovarian malignancy was 73.3% (n=22).
Conclusion: CA 19-9 is elevated in more than two-thirds of the patients with ovarian cancer.

Downloads

Published

2019-10-07

How to Cite

Tahir, A. A., Kamal, S., & Waheed, R. (2019). THE FREQUENCY AND CLINICAL USEFULNESS OF CA 19-9 IN THE WORK UP OF OVARIAN MALIGNANCY. Journal of Medical Sciences, 27(3), 161–163. Retrieved from https://jmedsci.com/Jmedsci/article/view/725

Issue

Section

Articles

Most read articles by the same author(s)

1 2 > >> 

Similar Articles

1 2 3 > >> 

You may also start an advanced similarity search for this article.